Evoke Pharma (EVOK) Short Interest Ratio & Short Volume → You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad) Free EVOK Stock Alerts $0.48 -0.07 (-12.76%) (As of 04/18/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Evoke Pharma Short Interest DataCurrent Short Volume53,400 sharesPrevious Short Volume72,100 sharesChange Vs. Previous Month-25.94%Dollar Volume Sold Short$32,574.00Short Interest Ratio / Days to Cover0.9Last Record DateMarch 31, 2024Outstanding Shares8,480,000 sharesFloat Size6,840,000 sharesShort Percent of Float0.78%Today's Trading Volume20,940 sharesAverage Trading Volume24,321 sharesToday's Volume Vs. Average86% Short Selling Evoke Pharma ? Sign up to receive the latest short interest report for Evoke Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatEVOK Short Interest Over TimeEVOK Days to Cover Over TimeEVOK Percentage of Float Shorted Over Time Ad Paradigm PressAI “wealth window” is closing soon!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… Evoke Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202453,400 shares $32,574.00 -25.9%0.8%0.9 $0.61 3/15/202472,100 shares $44,702.00 +21.8%1.1%1.2 $0.62 2/29/202459,200 shares $39,184.48 -73.1%0.7%1.1 $0.66 2/15/2024219,800 shares $153,860.00 -46.1%2.7%4.3 $0.70 1/31/2024407,900 shares $277,372.00 +419.0%12.5%9.1 $0.68 1/15/202478,600 shares $58,950.00 +83.2%2.4%2.2 $0.75 Get the Latest News and Ratings for EVOK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. 12/31/202342,900 shares $45,057.87 +371.4%1.3%3.4 $1.05 12/15/20239,100 shares $10,920.00 -43.8%0.3%0.6 $1.20 11/30/202316,200 shares $21,019.50 -28.0%0.5%1.2 $1.30 11/15/202322,500 shares $28,575.00 +54.1%0.7%1.8 $1.27 10/31/202314,600 shares $16,936.00 -51.8%0.5%1.1 $1.16 10/15/202330,300 shares $38,484.03 +41.6%0.9%2 $1.27 9/30/202321,400 shares $29,532.00 +20.9%0.7%1.4 $1.38 9/15/202317,700 shares $20,532.00 +391.7%0.5%1.4 $1.16 8/31/20233,600 shares $4,467.60 -76.9%0.1%0.1 $1.24 8/15/202315,600 shares $20,280.00 +136.4%0.5%0.6 $1.30 7/31/20236,600 shares $10,692.00 +1.5%0.2%0.2 $1.62 7/15/20236,500 shares $11,051.30 -57.0%0.2%0.2 $1.70 6/30/202315,100 shares $24,764.00 -65.8%0.5%0.5 $1.64 6/15/202344,100 shares $73,232.46 +390.0%1.4%1.4 $1.66 5/31/20239,000 shares $14,670.00 -65.5%0.3%0.4 $1.63 5/15/202326,100 shares $50,265.99 +107.1%0.8%1.5 $1.93 4/30/202312,600 shares $23,640.12 +12.5%0.4%0.7 $1.88 4/15/202311,200 shares $21,728.00 -7.4%0.3%0.4 $1.94 3/31/202312,100 shares $22,990.00 -67.5%0.4%0.4 $1.90 3/15/202337,200 shares $122,760.00 +42.5%1.1%1 $3.30 2/28/202326,100 shares $75,951.00 +54.4%0.8%0.6 $2.91 2/15/202316,900 shares $47,827.00 -71.1%0.5%0.4 $2.83 1/31/202358,500 shares $236,340.00 +61.2%1.8%1.5 $4.04 1/15/202336,300 shares $111,804.00 -33.9%1.1%1.2 $3.08 12/30/202254,900 shares $147,132.00 +42.2%1.7%2.2 $2.68 12/15/202238,600 shares $72,954.00 +27.4%1.2%1.8 $1.89 11/30/202230,300 shares $45,450.00 +14.8%0.9%1.6 $1.50 11/15/202226,400 shares $44,352.00 +7.8%0.8%1.9 $1.68 10/31/202224,500 shares $42,385.00 +12.9%0.8%1.3 $1.73 10/15/202221,700 shares $42,482.09 -18.4%0.7%0.7 $1.96 9/30/202226,600 shares $49,742.00 -25.7%0.8%0.8 $1.87 9/15/202235,800 shares $80,550.00 +26.1%1.1%0.8 $2.25 8/31/202228,400 shares $76,680.00 -52.5%N/A0 $2.70 8/15/202259,800 shares $163,852.00 +76.9%N/A0.1 $2.74AI “wealth window” is closing soon! (Ad)Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… EVOK Short Interest - Frequently Asked Questions What is Evoke Pharma's current short interest? Short interest is the volume of Evoke Pharma shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 53,400 shares of EVOK short. 0.78% of Evoke Pharma's shares are currently sold short. Learn More on Evoke Pharma's current short interest. What is a good short interest ratio for Evoke Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EVOK shares currently have a short interest ratio of 1.0. Learn More on Evoke Pharma's short interest ratio. Which institutional investors are shorting Evoke Pharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Evoke Pharma: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Evoke Pharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.78% of Evoke Pharma's floating shares are currently sold short. Is Evoke Pharma's short interest increasing or decreasing? Evoke Pharma saw a drop in short interest in March. As of March 31st, there was short interest totaling 53,400 shares, a drop of 25.9% from the previous total of 72,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Evoke Pharma's float size? Evoke Pharma currently has issued a total of 8,480,000 shares. Some of Evoke Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Evoke Pharma currently has a public float of 6,840,000 shares. How does Evoke Pharma's short interest compare to its competitors? 0.78% of Evoke Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Evoke Pharma: Cingulate Inc. (1.21%), Virpax Pharmaceuticals, Inc. (3.42%), Biophytis S.A. (0.73%), Mustang Bio, Inc. (2.35%), Kintara Therapeutics, Inc. (1.69%), NexImmune, Inc. (2.26%), Tharimmune, Inc. (0.65%), ZyVersa Therapeutics, Inc. (8.09%), Processa Pharmaceuticals, Inc. (1.56%), Genprex, Inc. (3.78%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Evoke Pharma stock? Short selling EVOK is an investing strategy that aims to generate trading profit from Evoke Pharma as its price is falling. EVOK shares are trading down $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Evoke Pharma? A short squeeze for Evoke Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EVOK, which in turn drives the price of the stock up even further. How often is Evoke Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EVOK, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: CING Short Interest Data VRPX Short Interest Data BPTS Short Interest Data MBIO Short Interest Data KTRA Short Interest Data NEXI Short Interest Data THAR Short Interest Data ZVSA Short Interest Data PCSA Short Interest Data GNPX Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EVOK) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe “Perfect Storm” for GoldGold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchUrgent alert: open this for a huge profit potentialTimothy SykesThe #1 Crypto for 2024InvestorPlace